CSX CORP (CSX)       30.08  -0.07 (-0.23%)

30.08  -0.07 (-0.23%)

US1264081035 - Common Stock - After market: 30.08 0 (0%)


Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to CSX. CSX was compared to 48 industry peers in the Road & Rail industry. Both the profitability and the financial health of CSX get a neutral evaluation. Nothing too spectacular is happening here. While showing a medium growth rate, CSX is valued expensive at the moment.




Profitability

Profitability Rating

6

CSX's Return On Equity of 31.71% is amongst the best of the industry. CSX does better than the industry average Return On Equity of 23.92%.
CSX's Profit Margin of 28.05% is amongst the best returns of the industry. CSX outperforms 83% of its industry peers. The industry average Profit Margin is 10.90%.

CSX has a good Piotroski-F score of 7.00. This indicates a good health and good profitability for CSX.
CSX has a Return On Assets of 9.66%. This is comparable to the industry average of 9.66%.
VS Industry

ROA (9.66%) VS Industry: 51% outperformed.

1.57
27.69

ROE (31.71%) VS Industry: 66% outperformed.

1.75
60.21

Profit Margin (28.05%) VS Industry: 83% outperformed.

2.59
33.10

Valuation

Valuation Rating

3

The low PEG Ratio, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The Price/Earnings Ratio is 16.17, which indicates a correct valuation of CSX.
With a Forward Price/Earnings Ratio of 15.67, CSX is valued correctly.
When comparing the current price to the book value of CSX, we can conclude it is valued correctly. It is trading at 4.91 times its book value.

CSX's Price/Earning Ratio is slightly more expensive than the industry average, which is at 13.87.
Compared to an average industry price book ratio of 2.26, CSX is valued more expensive than its industry peers. 81% of the companies listed in the same industry are valued cheaper.
When comparing the Enterprise Value to EBITDA ratio of CSX to the average industry ratio of 8.04, CSX is valued more expensive than its industry peers.
VS Industry

Price/Earnings (16.17) VS Industry: 37% outperformed.

93.13
1.25

Price/Book (4.91) VS Industry: 19% outperformed.

11.19
0.26

Enterprise Value/ EBITDA (10.96) VS Industry: 33% outperformed.

44.46
3.28

Growth

Growth Rating

6

The Earnings Per Share has grown by an impressive 25.96% over the past year.
CSX shows a strong growth in Earnings Per Share. Measured over the last 5 years, the EPS has been growing by 20.77% yearly.
CSX shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.06%.
The Revenue growth is accelerating: in the next 5 years the growth will be better than in the last years.

The Earnings Per Share is expected to grow by 9.13% on average over the next 5 years.
The Revenue has been growing slightly by 2.50% on average over the past 5 years.
Based on estimates for the next 5 years, CSX will show a small growth in Revenue. The Revenue will grow by 5.01% on average per year.
The EPS growth is decreasing: in the next 5 years the growth will be less than in the last years.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPS20.77% 6.5% 25.96% 23.62% 11.29% 10.3% 9.13%
Revenue2.5% 0.73% 22.06% 19.97% 8.9% 6.84% 5.01%

Health

Health Rating

6

CSX is better placed than average in its industry to meet its short term obligations. Its Current Ratio is much better than the industry average of 1.30.
When comparing the Quick Ratio to an average industry Quick Ratio of 1.27, CSX is better placed than the average industry peer to meet its short term obligations.
The Piotroski-F score of CSX is 7.00. This is a strong score and indicates good health and profitability for CSX.
CSX has a Current Ratio of 1.72. This is a normal value and indicates that CSX is financially healthy and should not expect problems in meeting its short term obligations.

A Quick Ratio of 1.57 indicates that CSX should not have too much problems paying its short term obligations.
CSX has an Altman-Z score of 2.48. This is not the best score and indicates that CSX is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score is in line with the industry averages, which is at 2.46.
Compared to an average industry Debt to Equity Ratio of 0.53, CSX is requires more financing than its industry peers. 83% of its industry peers have a better Debt to Equity Ratio.
VS Industry

Debt/Equity (1.39) VS Industry: 17% outperformed.

5.00
0.00

Quick Ratio (1.57) VS Industry: 63% outperformed.

0.29
18.34

Current Ratio (1.72) VS Industry: 75% outperformed.

0.29
18.34

Altman-Z (2.48) VS Industry: 55% outperformed.

-20.50
21.24

Dividend

Dividend Rating

6

On average, the dividend of CSX grows each year by 8.34%, which is quite nice.
CSX's earnings are growing more than its dividend. This makes the dividend growth sustainable.
CSX pays out 20.85% of its income as dividend. This is a sustainable payout ratio.
CSX has paid a dividend for at least 10 years, which is a reliable track record.

CSX has a Yearly Dividend Yield of 1.25%. Purely for dividend investing, there may be better candidates out there.
CSX's Dividend Yield is comparable with the industry average which is at 1.25.
Compared to an average S&P500 Dividend Yield of 2.41, CSX's dividend is way lower than the S&P500 average.
VS Industry

Dividend Yield (1.25%) VS Industry: 50% outperformed.

0.38
5.26

CSX CORP30.08

NASDAQ:CSX (1/27/2023, 7:01:34 PM)-0.07 (-0.23%)

After market: 30.08 0 (0%)

Chartmill FA Rating
GICS Sector Industrials
GICS IndustryGroup Transportation
GICS Industry Road & Rail
Earnings (Last) 01-18 2023-01-18 Earnings (Next) 04-18 2023-04-18
Inst Owners 74.91% Inst Owner Change -0.02%
Ins Owners 0.11% Ins Owner Change 10.86%
Market Cap 63.24B Analysts 76.47
Price Target 34.51 (14.73%)

Dividend
Dividend Yield 1.25% Dividend Growth 8.34%
DP 20.85% Ex-Date N/A

Surprises & Revisions
EPS beat(2) 2 Avg EPS beat(2) 8.09%
Min EPS beat(2) 2.37% Max EPS beat(2) 13.8%
EPS beat(4) 4 Avg EPS beat(4) 5.01%
Min EPS beat(4) 0.44% Max EPS beat(4) 13.8%
Revenue beat(2) 2 Avg Revenue beat(2) 3.22%
Min Revenue beat(2) 3.02% Max Revenue beat(2) 3.42%
Revenue beat(4) 4 Avg Revenue beat(4) 2.71%
Min Revenue beat(4) 2.15% Max Revenue beat(4) 3.42%
PT rev (1m) 1.68% EPS NQ rev (1m) 0%
EPS NY rev (1m) 0% Revenue NQ rev (1m) 0%
Revenue NY rev (1m) 0%

Valuation
Industry RankSector Rank
PE 16.17
Fwd PE 15.67
P/S 4.35
P/FCF 17.93
P/OCF 11.43
P/B 4.91
P/tB 5.13
EV/EBITDA 10.96
EPS(TTM) 1.86 EY 6.18%
EPS(NY) 1.92 Fwd EY 6.38%
FCF(TTM) 1.68 FCFY 5.58%
OCF(TTM) 2.63 OCFY 8.75%
SpS 6.92 BVpS 6.12
TBVpS 5.87 PEG (NY) 0.68
PEG (5Y) 0.78

Profitability
Industry RankSector Rank
ROA 9.66%
ROE 31.71%
ROIC 10.99%
ROICexc 11.7%
ROICexgc 11.87%
OM 39.33%
PM 28.05%
GM 71.63%
ROICexgc(3y) 10.51% ROICexcg growth 3Y 0.71%
ROICexcg growth 5Y 6.83% ROICexc(3y) 10.47%
ROICexc growth 3Y 0.29% ROICexc growth 5Y 6.57%
OM growth 3Y 1.75% OM growth 5Y 6.2%
PM growth 3Y 3.79% PM growth 5Y 14.3%
GM growth 3Y 0.11% GM growth 5Y 0.27%
F-Score 7 Asset Turnover 0.34

Health
Industry RankSector Rank
Debt/Equity 1.39
Debt/FCF 5.12
Debt/EBITDA 2.51
Cap/Depr 136.88%
Profit Quality 86.4%
Current Ratio 1.72
Quick Ratio 1.57
Altman-Z 2.48
F-Score 7 WACC 9.33%
ROIC/WACC 1.27 Cap/Depr(3y) 122.18%
Cap/Depr(5y) 130.55% Profit Quality(3y) 92.91%
Profit Quality(5y) 78.49%

Growth
EPS 1Y 25.96% EPS 3Y 6.5%
EPS 5Y 20.77% EPS growth Q2Q 18.6%
EPS Next Y 23.62% EPS Next 2Y 11.29%
EPS Next 3Y 10.3% EPS Next 5Y 9.13%
Revenue growth 1Y 22.06% Revenue growth 3Y 0.73%
Revenue growth 5Y 2.5% Revenue growth Q2Q 18.32%
Revenue Next Year 19.97% Revenue Next 2Y 8.9%
Revenue Next 3Y 6.84% Revenue Next 5Y 5.01%
EBIT growth 1Y 14.09% EBIT growth 3Y 2.5%
EBIT growth 5Y 8.85% EBIT Next Year 40.71%
EBIT Next 3Y 12.63% EBIT Next 5Y 8.92%
FCF growth 1Y 37.45% FCF growth 3Y 4.53%
FCF growth 5Y 38.76% OCF growth 1Y 30.51%
OCF growth 3Y 3.19% OCF growth 5Y 10.89%

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA